SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

GE Healthcare reports mangaciclanol well tolerated in Phase 2

A website report says mangaciclanol was well tolerated, with no safety concerns, in a Phase 2 study.

GEHC

Related stories